Thanks guys, be assured I haven't abandoned investors in GDN, mearly protecting my interests or what is left of them right now. I am very much still following the company.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
